Verseon Token


Verseon logo

The Raise Total


Price Per Token


Raise Start


Minimum Investment


Verseon is a technology-based drug discovery company founded in 2002. Our proprietary, computer-driven drug discovery platform uses computational chemistry, physics-based molecular modeling, and optimization embedded into a comprehensive in-house laboratory workflow to identify novel drug candidates faster and more inexpensively than conventional methods


Fundraise Information

Total Raise $0 USD
Soft Cap -
Raise Status -
Minimum Investment $0 USD
Accepted Investors U.S. - Accredited
Security Type Revenue Sharing
Exemptions -
Instrument TBA

Token Information

Price Per (VERS) -
Token Issuance Platform -
Token Protocol I currently have not selected a protocol
Token Issuance Info -
Payment Options
  • USD

Token Rights

Each security token will be a form of preferred share that grants its holder rights to a percentage of Verseon’s future drug program revenues



Verseon plans to use its platform to establish a diversified discovery pipeline across multiple disease areas. Current drug programs include anticoagulation, diabetic macular edema, hereditary angioedema, and oncology (solid tumors). Verseon Corporation is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology




Adityo Prakash

Co-Founder & CEO

Eniko Fodor

Co-Founder & COO

David Kita

Co-Founder, Vice President of R&D